Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

导出 LinkOut

翻译打印收藏纠错

作者： Claudio,Jommi ^[1] ; Antonio,Addis ^[2] ; Nello,Martini ^[3] ; Elena,Nicod ^[4] ; Marcello,Pani ^[1] ; Annalisa,Scopinaro ^[5] ; Sabine,Vogler ^[6]

作者单位： Cergas SDA Bocconi School of Management, Milan - Italy. ^[1] Department of Epidemiology, Regional Health Service (Regione Lazio) Member of the Scientific Technical Committee, Italian Medicines Agency (AIFA), Rome - Italy. ^[2] Fondazione ReS (Research and Health Foundation), Rome - Italy. ^[3] Dolon Ltd, London - UK. ^[4] Agostino Gemelli IRCCS University Hospital Foundation, Rome - Italy. ^[5] UNIAMO (Italian Federation for Rare Diseases), Rome - Italy. ^[6] WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Austrian National Public Health Institute (GÖG), Vienna - Austria. ^[7]

关键词 Italy Managed entry agreements Orphan medicines Value framework

DOI 10.33393/grhta.2021.2278

PMID 36627869

发布时间 2023-01-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Global & regional health technology assessment

114-119页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

Global & regional health technology assessment

相似文献

Global & regional health technology assessment

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

Global & regional health technology assessment

相似文献

Global & regional health technology assessment

相关期刊

检索历史清除